BridgeMD
Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment
EU CTIS ID: 2025-523921-17-00
What this study is testing
To demonstrate a decrease in serum calprotectin levels at 3 months in the anakinra arm compared with the standard of care.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
- - Stable cytoreductive therapy for at least 6 months
- - Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
- - Adult patient capable of providing informed consent
You likely can't join if
- - Recurrent or poorly controlled infections
- - Lack of understanding of questionnaires or inability to follow up.
- - Women of childbearing potential unwilling to use appropriate contraception.
- - Thrombocytopenia < 100 G/L
- - Neutropenia < 1 G/L
- - Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
See the full eligibility criteria
- - Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
- - Stable cytoreductive therapy for at least 6 months
- - Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
- - Adult patient capable of providing informed consent
- - Recurrent or poorly controlled infections
- - Lack of understanding of questionnaires or inability to follow up.
- - Women of childbearing potential unwilling to use appropriate contraception.
- - Thrombocytopenia < 100 G/L
- - Neutropenia < 1 G/L
- - Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
- - Concomitant immunosuppressive therapy
- - Refusal to participate
- - Patient under legal protection (guardianship, curatorship, etc.)
- - Patients unable to consent.
- - Pregnant or breastfeeding women.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.